A Phase 2 interventional study of Vamikibart and Ranibizumab in Diabetic Macular Edema, sponsored by Hoffmann-La Roche. Completed at 38 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-10-16.
Sponsored by Hoffmann-La Roche · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 28 studies in Macular Edema by Hoffmann-La Roche — 1 open to participants now, 5 under way, 1 of them phase 3. Macular Edema · Hoffmann-La Roche.
Among the 28 studies in Macular Edema by Hoffmann-La Roche, this one is the 19th largest by enrollment of the 25 interventional ones that give a count, is one of 4 that started in 2021, is one of 4 in phase 2, and was the 17th registered.
758 studies on the registry are indexed under Macular Edema; 65 are open to participants now.
Browse Macular Edema studies →1 of the 28 studies in Macular Edema by Hoffmann-La Roche is open now, in 1 country. Recruiting first, the newest first:
Genentech, Inc. · Sites in United States
Ages 18+
By country, each count listing its studies:
Of the 43 Macular Edema studies recruiting now, 31 (72%) set no upper age limit and 7 (16%) stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
28 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 5 · Phase 3 14 · Phase 4 2
First in 2007; this study’s year is marked. 4 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 187 is above the median of 56 across 586 interventional studies indexed under Macular Edema.
Median enrollment 377 across the 25 interventional studies, 736 across the 3 observational. Of the 23 that completed or were terminated, 17 (74%) have results posted.
This tab as a report to print or save as PDF → With an account.
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
3 of the studies in Macular Edema by Hoffmann-La Roche that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04108156Phase 3Hoffmann-La RocheA Study to Evaluate Efficacy, Safety & Pharmacokinetics of the Port Delivery System (PDS) With Ranibizumab in Participants With Diabetic Macular Edema (DME) Compared With Intravitreal Ranibizumab; A Substudy to Evaluate the Safety of Re-implanting the PDS With Ranibizumab in Participants With DME | 2027-07-20 |
| NCT05224102Genentech, Inc.A Study to Investigate Faricimab Treatment Response in Treatment-Naive, Underrepresented Patients With Diabetic Macular Edema | 2027-01-26 |
| NCT06680817Hoffmann-La RocheA Real-World Study to Gain Clinical Insights Into Faricimab (FaReal Study) | 2027-06-30 |
Add all 3 to your calendar (.ics) → With an account.
Among the 28 studies in Macular Edema by Hoffmann-La Roche, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Study BP43464 is a phase II, multicenter, randomized, double-masked active comparator-controlled study designed to assess the efficacy, safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of vamikibart in combination with, anti-vascular endothelial growth factor (VEGF) inhibitor, ranibizumab compared with ranibizumab alone in participants with diabetic macular edema. Only one eye will be chosen as the study eye. The duration of the study will be 76 weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive vamikibart, 1 milligram (mg) administered as intravitreal (IVT) injection in combination with ranibizumab, 0.5 mg IVT, on Day 1 and every fourth week (Q4W) up to Week 44, for a total of 12 injections, followed by an observational period up to Week 72.
Drug: Vamikibart · Drug: Ranibizumab
Participants will receive ranibizumab, 0.5 mg IVT, from Day 1 and Q4W in combination with sham up to Week 44, for a total of 12 injections, followed by an observational period up to Week 72.
Drug: Ranibizumab · Other: Sham Procedure
Vamikibart will be administered by IVT injection in the study eye.
Also known as: RO7200220
Ranibizumab will be administered by IVT injection in the study eye.
Also known as: Lucentis
Sham is a procedure that mimics an IVT injection and involves the blunt end of an empty syringe (without a needle) being pressed against the anesthetized eye.
Change From Baseline in Best Corrected Visual Acuity (BCVA) Averaged Over Week 44 and Week 48 in Treatment-naïve Participants
BCVA was measured via Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters using a set of three Precision vision\^TM or Lighthouse distance acuity charts (modified ETDRS Charts 1, 2, and R) prior to dilating eyes by a trained and certified visual acuity (VA) examiner. The BCVA letter score ranges from 0 to 100 letters. Higher scores and gain in BCVA from baseline indicate improvement in VA. This analysis used a Mixed Model for Repeated Measurements (MMRM) model.
Time frame: Baseline, Week 44 and Week 48
Number of Participants With Systemic and Ocular Adverse Events (AEs)
An AE was any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product, regardless of causal attribution. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Systemic AEs include all non-ocular AEs.
Time frame: Up to Week 72
Change From Baseline in BCVA Averaged Over Week 44 and Week 48 in Previously Treated Participants
BCVA was measured via ETDRS chart at a starting distance of 4 meters using a set of three Precision vision\^TM or Lighthouse distance acuity charts (modified ETDRS Charts 1, 2, and R) prior to dilating eyes by a trained and certified VA examiner. The BCVA letter score ranges from 0 to 100 letters. Higher scores and gain in BCVA from baseline indicate improvement in VA. This analysis used a MMRM model.
Time frame: Baseline, Week 44 and Week 48
Change From Baseline in BCVA Averaged Over Week 44 and Week 48 in Overall ITT Population
BCVA was measured via ETDRS chart at a starting distance of 4 meters using a set of three Precision vision\^TM or Lighthouse distance acuity charts (modified ETDRS Charts 1, 2, and R) prior to dilating eyes by a trained and certified VA examiner. The BCVA letter score ranges from 0 to 100 letters. Higher scores and gain in BCVA from baseline indicate improvement in VA. This analysis used a MMRM model.
Time frame: Baseline, Week 44 and Week 48
Change From Baseline in BCVA Averaged Over Week 32 and Week 36, in Treatment-naïve Participants
BCVA was measured via ETDRS chart at a starting distance of 4 meters using a set of three Precision vision\^TM or Lighthouse distance acuity charts (modified ETDRS Charts 1, 2, and R) prior to dilating eyes by a trained and certified VA examiner. The BCVA letter score ranges from 0 to 100 letters. Higher scores and gain in BCVA from baseline indicate improvement in VA. This analysis used a MMRM model.
Time frame: Baseline, Week 32 and Week 36
Change From Baseline in BCVA Averaged Over Week 32 and Week 36, in Previously Treated Participants
BCVA was measured via ETDRS chart at a starting distance of 4 meters using a set of three Precision vision\^TM or Lighthouse distance acuity charts (modified ETDRS Charts 1, 2, and R) prior to dilating eyes by a trained and certified VA examiner. The BCVA letter score ranges from 0 to 100 letters. Higher scores and gain in BCVA from baseline indicate improvement in VA. This analysis used a MMRM model.
Time frame: Baseline, Week 32 and Week 36
Change From Baseline in BCVA Averaged Over Week 32 and Week 36, in Overall ITT Population
BCVA was measured via ETDRS chart at a starting distance of 4 meters using a set of three Precision vision\^TM or Lighthouse distance acuity charts (modified ETDRS Charts 1, 2, and R) prior to dilating eyes by a trained and certified VA examiner. The BCVA letter score ranges from 0 to 100 letters. Higher scores and gain in BCVA from baseline indicate improvement in VA. This analysis used a MMRM model.
Time frame: Baseline, Week 32 and Week 36
Change From Baseline in BCVA Averaged Over Week 20 and Week 24 in Treatment-naïve Participants
BCVA was measured via ETDRS chart at a starting distance of 4 meters using a set of three Precision vision\^TM or Lighthouse distance acuity charts (modified ETDRS Charts 1, 2, and R) prior to dilating eyes by a trained and certified VA examiner. The BCVA letter score ranges from 0 to 100 letters. Higher scores and gain in BCVA from baseline indicate improvement in VA. This analysis used a MMRM model.
Time frame: Baseline, Week 20 and Week 24
Change From Baseline in BCVA Averaged Over Week 20 and Week 24 in Previously Treated Participants
BCVA was measured via ETDRS chart at a starting distance of 4 meters using a set of three Precision vision\^TM or Lighthouse distance acuity charts (modified ETDRS Charts 1, 2, and R) prior to dilating eyes by a trained and certified VA examiner. The BCVA letter score ranges from 0 to 100 letters. Higher scores and gain in BCVA from baseline indicate improvement in VA. This analysis used a MMRM model.
Time frame: Baseline, Week 20 and Week 24
Change From Baseline in BCVA Averaged Over Week 20 and Week 24, in Overall ITT Population
BCVA was measured via ETDRS chart at a starting distance of 4 meters using a set of three Precision vision\^TM or Lighthouse distance acuity charts (modified ETDRS Charts 1, 2, and R) prior to dilating eyes by a trained and certified VA examiner. The BCVA letter score ranges from 0 to 100 letters. Higher scores and gain in BCVA from baseline indicate improvement in VA. This analysis used a MMRM model.
Time frame: Baseline, Week 20 and Week 24
Change From Baseline in BCVA Over Time in Overall ITT Population
BCVA was measured via ETDRS chart at a starting distance of 4 meters using a set of three Precision vision\^TM or Lighthouse distance acuity charts (modified ETDRS Charts 1, 2, and R) prior to dilating eyes by a trained and certified VA examiner. The BCVA letter score ranges from 0 to 100 letters. Higher scores and gain in BCVA from baseline indicate improvement in VA. This analysis used a MMRM model.
Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, and 72
Percentage of Participants Gaining ≥ 15, ≥ 10, ≥ 5, or ≥ 0 Letters in BCVA Over Time in Overall ITT Population
BCVA was measured via ETDRS chart at a starting distance of 4 meters using a set of three Precision vision\^TM or Lighthouse distance acuity charts (modified ETDRS Charts 1, 2, and R) prior to dilating eyes by a trained and certified VA examiner. The BCVA letter score ranges from 0 to 100 letters. Higher scores indicate improvement in VA. Percentages have been rounded off.
Time frame: Up to Week 72
Percentage of Participants Losing ≥ 15, ≥ 10, or ≥ 5 Letters in BCVA Over Time in Overall ITT Population
BCVA was measured via ETDRS chart at a starting distance of 4 meters using a set of three Precision vision\^TM or Lighthouse distance acuity charts (modified ETDRS Charts 1, 2, and R) prior to dilating eyes by a trained and certified VA examiner. The BCVA letter score ranges from 0 to 100 letters. Higher scores indicate improvement in VA. Percentages have been rounded off.
Time frame: Up to Week 72
Percentage of Participants With BCVA ≥ 69 Letters (20/40 Snellen Equivalent) Over Time
BCVA was measured via ETDRS chart at a starting distance of 4 meters using a set of three Precision vision\^TM or Lighthouse distance acuity charts (modified ETDRS Charts 1, 2, and R) prior to dilating eyes by a trained and certified VA examiner. The BCVA letter score ranges from 0 (Snellen equivalent \<20/800) to 100 (Snellen equivalent of 20/10) letters. Higher scores indicate improvement in VA. Percentages have been rounded off.
Time frame: Baseline, Weeks 1, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, and 72
Percentage of Participants With BCVA ≥ 84 Letters (20/20 Snellen Equivalent) Over Time
BCVA was measured via ETDRS chart at a starting distance of 4 meters using a set of three Precision vision\^TM or Lighthouse distance acuity charts (modified ETDRS Charts 1, 2, and R) prior to dilating eyes by a trained and certified VA examiner. The BCVA letter score ranges from 0 (Snellen equivalent \<20/800) to 100 (Snellen equivalent of 20/10) letters. Higher scores indicate improvement in VA. Percentages have been rounded off.
Time frame: Baseline, Weeks 1, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, and 72
Percentage of Participants With BCVA ≤ 38 Letters (20/200 Snellen Equivalent) Over Time
BCVA was measured via ETDRS chart at a starting distance of 4 meters using a set of three Precision vision\^TM or Lighthouse distance acuity charts (modified ETDRS Charts 1, 2, and R) prior to dilating eyes by a trained and certified VA examiner. The BCVA letter score ranges from 0 (Snellen equivalent \<20/800) to 100 (Snellen equivalent of 20/10) letters. Higher scores indicate improvement in VA. Percentages have been rounded off.
Time frame: Baseline, Weeks 1, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, and 72
Change From Baseline in Central Subfield Thickness (CST) Averaged Over Week 44 and Week 48 in Treatment-naïve Participants
CST was defined as the mean thickness from the inner limiting membrane to the retinal pigment epithelial over the 1 millimetre (mm) central subfield. CST was measured using spectral domain optical coherence tomography (SD-OCT). Negative change from baseline values denotes improvement. This analysis used a MMRM model.
Time frame: Baseline, Week 44 and Week 48
Change From Baseline in CST Averaged Over Week 44 and Week 48 in Previously Treated Participants
CST was defined as the mean thickness from the inner limiting membrane to the retinal pigment epithelial over the 1 mm central subfield. CST was measured using SD-OCT. Negative change from baseline values denotes improvement. This analysis used a MMRM model.
Time frame: Baseline, Week 44 and Week 48
Change From Baseline in CST Averaged Over Week 44 and Week 48 in Overall ITT Population
CST was defined as the mean thickness from the inner limiting membrane to the retinal pigment epithelial over the 1 mm central subfield. CST was measured using SD-OCT. Negative change from baseline values denotes improvement. This analysis used an MMRM model.
Time frame: Baseline, Week 44 and Week 48
Change From Baseline in CST Averaged Over Week 32 and Week 36 in Treatment-naïve Participants
CST was defined as the mean thickness from the inner limiting membrane to the retinal pigment epithelial over the 1 mm central subfield. CST was measured using SD-OCT. Negative change from baseline values denotes improvement. This analysis used an MMRM model.
Time frame: Baseline, Week 32 and Week 36
Change From Baseline in CST Averaged Over Week 32 and Week 36 in Previously Treated Participants
CST was defined as the mean thickness from the inner limiting membrane to the retinal pigment epithelial over the 1 mm central subfield. CST was measured using SD-OCT. Negative change from baseline values denotes improvement. This analysis used an MMRM model.
Time frame: Baseline, Week 32 and Week 36
Change From Baseline Averaged Over Week 32 and Week 36 in Overall ITT Population
CST was defined as the mean thickness from the inner limiting membrane to the retinal pigment epithelial over the 1 mm central subfield. CST was measured using SD-OCT. Negative change from baseline values denotes improvement. This analysis used an MMRM model.
Time frame: Baseline, Week 32 and Week 36
Change From Baseline in CST Averaged Over Week 20 and Week 24 in Treatment-naïve Participants
CST was defined as the mean thickness from the inner limiting membrane to the retinal pigment epithelial over the 1 mm central subfield. CST was measured using SD-OCT. Negative change from baseline values denotes improvement. This analysis used an MMRM model.
Time frame: Baseline, Week 20 and Week 24
Change From Baseline in CST Averaged Over Week 20 and Week 24 in Previously Treated Participants
CST was defined as the mean thickness from the inner limiting membrane to the retinal pigment epithelial over the 1 mm central subfield. CST was measured using SD-OCT. Negative change from baseline values denotes improvement. This analysis used an MMRM model.
Time frame: Baseline, Week 20 and Week 24
Change From Baseline in CST Averaged Over Week 20 and Week 24 in Overall ITT Population
CST was defined as the mean thickness from the inner limiting membrane to the retinal pigment epithelial over the 1 mm central subfield. CST was measured using SD-OCT. Negative change from baseline values denotes improvement. This analysis used an MMRM model.
Time frame: Baseline, Week 20 and Week 24
Change From Baseline in CST Over Time in Overall ITT Population
CST was defined as the mean thickness from the inner limiting membrane to the retinal pigment epithelial over the 1 mm central subfield. CST was measured using SD-OCT. Negative change from baseline values denotes improvement. This analysis used an MMRM model.
Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, and 72
Percentage of Participants With Absence of DME Over Time in Overall ITT Population
Absence of DME was defined as CST \< 325 μm for Spectralis SD-OCT, or \< 315 μm for Cirrus SD-OCT or Topcon SD-OCT. Percentages have been rounded off.
Time frame: Baseline, Weeks 4, 8, 12, 16, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, and 72
Percentage of Participants With Absence of Intraretinal Fluid (IRF) Over Time in Overall ITT Population
The absence of IRF in the study eye (defined as IRF absent or definite outside center subfield only) was assessed by the central reading center using SD-OCT. The percentage of participants with absence of IRF at foveal center are reported. Percentages have been rounded off.
Time frame: Baseline, Weeks 4, 12, 24, 36, 48, and 72
Percentage of Participants With Absence of Subretinal Fluid (SRF) Over Time in Overall ITT Population
The absence of SRF in the study eye (defined as SRF absent or definite outside center subfield only) was assessed by the central reading center using SD-OCT. The percentage of participants with absence of SRF at the foveal center are reported. Percentages have been rounded off.
Time frame: Baseline, Weeks 4, 12, 24, 36, 48, and 72
A total of 187 participants with diabetic macular edema (DME) took part in the study at 37 investigative sites across the United States, Argentina, Israel, South Korea, Poland, Canada, Spain, and the United Kingdom from 17 December 2021 to 1 October 2024.
| Milestone | Arm A: Vamikibart + Ranibizumab | Arm B: Ranibizumab |
|---|---|---|
| Started | 93 | 94 |
| Previously-treated intent-to-treat (itt) population | 32 | 31 |
| Treatment-naive itt population | 61 | 63 |
| Completed | 64 | 81 |
| Not completed | 29 | 13 |
| Withdrew: Adverse event | 6 | 2 |
| Withdrew: Death | 1 | 2 |
| Withdrew: Lack of efficacy | 1 | 1 |
| Withdrew: Lost to follow-up | 2 | 2 |
| Withdrew: Need for rescue treatment | 0 | 1 |
| Withdrew: Non-compliance with study drug | 0 | 1 |
| Withdrew: Reason not specified | 10 | 0 |
| Withdrew: Physician decision | 2 | 1 |
| Withdrew: Protocol violation | 1 | 0 |
| Withdrew: Withdrawal by subject | 6 | 3 |
BCVA was measured via Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters using a set of three Precision vision\^TM or Lighthouse distance acuity charts (modified ETDRS Charts 1, 2, and R) prior to dilating eyes by a trained and certified visual acuity (VA) examiner. The BCVA letter score ranges from 0 to 100 letters. Higher scores and gain in BCVA from baseline indicate improvement in VA. This analysis used a Mixed Model for Repeated Measurements (MMRM) model.
| letters | Arm A: Vamikibart + Ranibizumab | Arm B: Ranibizumab |
|---|---|---|
| Change From Baseline in Best Corrected Visual Acuity (BCVA) Averaged Over Week 44 and Week 48 in Treatment-naïve Participants | 12.8 ± 1.30 | 9.4 ± 1.25 |
An AE was any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product, regardless of causal attribution. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Systemic AEs include all non-ocular AEs.
| Participants | Arm A: Vamikibart + Ranibizumab | Arm B: Ranibizumab |
|---|---|---|
| Systemic AEs | 54 | 60 |
| Ocular AEs in Study Eyes | 33 | 28 |
| Ocular AEs in Fellow Eyes | 25 | 27 |
BCVA was measured via ETDRS chart at a starting distance of 4 meters using a set of three Precision vision\^TM or Lighthouse distance acuity charts (modified ETDRS Charts 1, 2, and R) prior to dilating eyes by a trained and certified VA examiner. The BCVA letter score ranges from 0 to 100 letters. Higher scores and gain in BCVA from baseline indicate improvement in VA. This analysis used a MMRM model.
| letters | Arm A: Vamikibart + Ranibizumab | Arm B: Ranibizumab |
|---|---|---|
| Change From Baseline in BCVA Averaged Over Week 44 and Week 48 in Previously Treated Participants | 11.1 ± 1.50 | 8.4 ± 1.49 |
BCVA was measured via ETDRS chart at a starting distance of 4 meters using a set of three Precision vision\^TM or Lighthouse distance acuity charts (modified ETDRS Charts 1, 2, and R) prior to dilating eyes by a trained and certified VA examiner. The BCVA letter score ranges from 0 to 100 letters. Higher scores and gain in BCVA from baseline indicate improvement in VA. This analysis used a MMRM model.
| letters | Arm A: Vamikibart + Ranibizumab | Arm B: Ranibizumab |
|---|---|---|
| Change From Baseline in BCVA Averaged Over Week 44 and Week 48 in Overall ITT Population | 12.4 ± 0.99 | 9.1 ± 0.96 |
BCVA was measured via ETDRS chart at a starting distance of 4 meters using a set of three Precision vision\^TM or Lighthouse distance acuity charts (modified ETDRS Charts 1, 2, and R) prior to dilating eyes by a trained and certified VA examiner. The BCVA letter score ranges from 0 to 100 letters. Higher scores and gain in BCVA from baseline indicate improvement in VA. This analysis used a MMRM model.
| letters | Arm A: Vamikibart + Ranibizumab | Arm B: Ranibizumab |
|---|---|---|
| Change From Baseline in BCVA Averaged Over Week 32 and Week 36, in Treatment-naïve Participants | 11.8 ± 0.97 | 9.3 ± 0.94 |
BCVA was measured via ETDRS chart at a starting distance of 4 meters using a set of three Precision vision\^TM or Lighthouse distance acuity charts (modified ETDRS Charts 1, 2, and R) prior to dilating eyes by a trained and certified VA examiner. The BCVA letter score ranges from 0 to 100 letters. Higher scores and gain in BCVA from baseline indicate improvement in VA. This analysis used a MMRM model.
| letters | Arm A: Vamikibart + Ranibizumab | Arm B: Ranibizumab |
|---|---|---|
| Change From Baseline in BCVA Averaged Over Week 32 and Week 36, in Previously Treated Participants | 8.3 ± 1.43 | 7.5 ± 1.46 |
BCVA was measured via ETDRS chart at a starting distance of 4 meters using a set of three Precision vision\^TM or Lighthouse distance acuity charts (modified ETDRS Charts 1, 2, and R) prior to dilating eyes by a trained and certified VA examiner. The BCVA letter score ranges from 0 to 100 letters. Higher scores and gain in BCVA from baseline indicate improvement in VA. This analysis used a MMRM model.
| letters | Arm A: Vamikibart + Ranibizumab | Arm B: Ranibizumab |
|---|---|---|
| Change From Baseline in BCVA Averaged Over Week 32 and Week 36, in Overall ITT Population | 10.6 ± 0.81 | 8.7 ± 0.80 |
BCVA was measured via ETDRS chart at a starting distance of 4 meters using a set of three Precision vision\^TM or Lighthouse distance acuity charts (modified ETDRS Charts 1, 2, and R) prior to dilating eyes by a trained and certified VA examiner. The BCVA letter score ranges from 0 to 100 letters. Higher scores and gain in BCVA from baseline indicate improvement in VA. This analysis used a MMRM model.
| letters | Arm A: Vamikibart + Ranibizumab | Arm B: Ranibizumab |
|---|---|---|
| Change From Baseline in BCVA Averaged Over Week 20 and Week 24 in Treatment-naïve Participants | 10.6 ± 1.04 | 8.5 ± 1.01 |
BCVA was measured via ETDRS chart at a starting distance of 4 meters using a set of three Precision vision\^TM or Lighthouse distance acuity charts (modified ETDRS Charts 1, 2, and R) prior to dilating eyes by a trained and certified VA examiner. The BCVA letter score ranges from 0 to 100 letters. Higher scores and gain in BCVA from baseline indicate improvement in VA. This analysis used a MMRM model.
| letters | Arm A: Vamikibart + Ranibizumab | Arm B: Ranibizumab |
|---|---|---|
| Change From Baseline in BCVA Averaged Over Week 20 and Week 24 in Previously Treated Participants | 8.1 ± 1.46 | 6.2 ± 1.47 |
BCVA was measured via ETDRS chart at a starting distance of 4 meters using a set of three Precision vision\^TM or Lighthouse distance acuity charts (modified ETDRS Charts 1, 2, and R) prior to dilating eyes by a trained and certified VA examiner. The BCVA letter score ranges from 0 to 100 letters. Higher scores and gain in BCVA from baseline indicate improvement in VA. This analysis used a MMRM model.
| letters | Arm A: Vamikibart + Ranibizumab | Arm B: Ranibizumab |
|---|---|---|
| Change From Baseline in BCVA Averaged Over Week 20 and Week 24, in Overall ITT Population | 9.7 ± 0.84 | 7.8 ± 0.83 |
BCVA was measured via ETDRS chart at a starting distance of 4 meters using a set of three Precision vision\^TM or Lighthouse distance acuity charts (modified ETDRS Charts 1, 2, and R) prior to dilating eyes by a trained and certified VA examiner. The BCVA letter score ranges from 0 to 100 letters. Higher scores and gain in BCVA from baseline indicate improvement in VA. This analysis used a MMRM model.
| letters | Arm A: Vamikibart + Ranibizumab | Arm B: Ranibizumab |
|---|---|---|
| Baseline | 62.6 ± 1.02 | 62.0 ± 1.01 |
| Change at Week 4 | 6.7 ± 0.64 | 4.2 ± 0.65 |
| Change at Week 8 | 7.6 ± 0.76 | 4.6 ± 0.76 |
| Change at Week 12 | 8.9 ± 0.78 | 6.4 ± 0.78 |
| Change at Week 16 | 9.3 ± 0.83 | 7.4 ± 0.83 |
| Change at Week 20 | 9.7 ± 0.81 | 7.6 ± 0.80 |
| Change at Week 24 | 9.8 ± 1.03 | 8.0 ± 1.02 |
| Change at Week 28 | 10.1 ± 0.87 | 8.5 ± 0.87 |
| Change at Week 32 | 10.5 ± 0.88 | 8.8 ± 0.87 |
| Change at Week 36 | 10.6 ± 0.84 | 8.6 ± 0.83 |
| Change at Week 40 | 10.9 ± 0.95 | 8.8 ± 0.93 |
| Change at Week 44 | 12.2 ± 1.01 | 8.7 ± 0.99 |
| Change at Week 48 | 12.5 ± 1.03 | 9.4 ± 1.00 |
| Change at Week 52 | 11.1 ± 1.07 | 8.0 ± 1.03 |
| Change at Week 56 | 10.8 ± 1.13 | 7.8 ± 1.09 |
| Change at Week 60 | 10.4 ± 1.18 | 7.7 ± 1.14 |
| Change at Week 64 | 10.2 ± 1.12 | 8.2 ± 1.10 |
| Change at Week 68 | 9.9 ± 1.14 | 7.6 ± 1.11 |
| Change at Week 72 | 9.2 ± 1.12 | 7.8 ± 1.11 |
BCVA was measured via ETDRS chart at a starting distance of 4 meters using a set of three Precision vision\^TM or Lighthouse distance acuity charts (modified ETDRS Charts 1, 2, and R) prior to dilating eyes by a trained and certified VA examiner. The BCVA letter score ranges from 0 to 100 letters. Higher scores indicate improvement in VA. Percentages have been rounded off.
| percentage of participants | Arm A: Vamikibart + Ranibizumab | Arm B: Ranibizumab |
|---|---|---|
| Participants Gaining ≥ 0 Letters | 98.9 | 98.9 |
| Participants Gaining ≥ 5 Letters | 94.6 | 90.4 |
| Participants Gaining ≥ 10 Letters | 76.3 | 69.1 |
| Participants Gaining ≥ 15 Letters | 49.5 | 44.7 |
BCVA was measured via ETDRS chart at a starting distance of 4 meters using a set of three Precision vision\^TM or Lighthouse distance acuity charts (modified ETDRS Charts 1, 2, and R) prior to dilating eyes by a trained and certified VA examiner. The BCVA letter score ranges from 0 to 100 letters. Higher scores indicate improvement in VA. Percentages have been rounded off.
| percentage of participants | Arm A: Vamikibart + Ranibizumab | Arm B: Ranibizumab |
|---|---|---|
| Participants Losing ≥ 5 Letters | 19.4 | 27.7 |
| Participants Losing ≥ 10 Letters | 7.5 | 11.7 |
| Participants Losing ≥ 15 Letters | 4.3 | 6.4 |
BCVA was measured via ETDRS chart at a starting distance of 4 meters using a set of three Precision vision\^TM or Lighthouse distance acuity charts (modified ETDRS Charts 1, 2, and R) prior to dilating eyes by a trained and certified VA examiner. The BCVA letter score ranges from 0 (Snellen equivalent \<20/800) to 100 (Snellen equivalent of 20/10) letters. Higher scores indicate improvement in VA. Percentages have been rounded off.
| percentage of participants | Arm A: Vamikibart + Ranibizumab | Arm B: Ranibizumab |
|---|---|---|
| Baseline | 34.4 | 31.9 |
| Week 1 | 53.4 | 48.9 |
| Week 4 | 63.0 | 53.3 |
| Week 8 | 67.0 | 48.9 |
| Week 12 | 73.0 | 56.5 |
| Week 16 | 69.7 | 57.5 |
| Week 20 | 74.7 | 67.0 |
| Week 24 | 70.6 | 61.6 |
| Week 28 | 71.8 | 63.2 |
| Week 32 | 78.8 | 62.5 |
| Week 36 | 72.6 | 62.7 |
| Week 40 | 78.4 | 70.6 |
| Week 44 | 82.1 | 67.1 |
| Week 48 | 80.9 | 70.4 |
| Week 52 | 78.6 | 64.2 |
| Week 56 | 82.1 | 58.7 |
| Week 60 | 82.0 | 68.8 |
| Week 64 | 82.5 | 69.8 |
| Week 68 | 81.1 | 71.4 |
| Week 72 | 82.7 | 71.1 |
BCVA was measured via ETDRS chart at a starting distance of 4 meters using a set of three Precision vision\^TM or Lighthouse distance acuity charts (modified ETDRS Charts 1, 2, and R) prior to dilating eyes by a trained and certified VA examiner. The BCVA letter score ranges from 0 (Snellen equivalent \<20/800) to 100 (Snellen equivalent of 20/10) letters. Higher scores indicate improvement in VA. Percentages have been rounded off.
| percentage of participants | Arm A: Vamikibart + Ranibizumab | Arm B: Ranibizumab |
|---|---|---|
| Baseline | 0 | 0 |
| Week 1 | 2.3 | 0 |
| Week 4 | 6.5 | 2.2 |
| Week 8 | 10.2 | 5.6 |
| Week 12 | 10.1 | 8.7 |
| Week 16 | 13.5 | 6.9 |
| Week 20 | 14.5 | 8.8 |
| Week 24 | 17.6 | 8.1 |
| Week 28 | 12.9 | 11.5 |
| Week 32 | 17.5 | 13.8 |
| Week 36 | 13.7 | 12.0 |
| Week 40 | 12.2 | 11.8 |
| Week 44 | 23.9 | 8.9 |
| Week 48 | 23.5 | 14.8 |
| Week 52 | 15.7 | 7.4 |
| Week 56 | 14.9 | 9.3 |
| Week 60 | 13.1 | 9.4 |
| Week 64 | 19.3 | 11.3 |
| Week 68 | 18.9 | 10.2 |
| Week 72 | 11.5 | 11.1 |
BCVA was measured via ETDRS chart at a starting distance of 4 meters using a set of three Precision vision\^TM or Lighthouse distance acuity charts (modified ETDRS Charts 1, 2, and R) prior to dilating eyes by a trained and certified VA examiner. The BCVA letter score ranges from 0 (Snellen equivalent \<20/800) to 100 (Snellen equivalent of 20/10) letters. Higher scores indicate improvement in VA. Percentages have been rounded off.
| percentage of participants | Arm A: Vamikibart + Ranibizumab | Arm B: Ranibizumab |
|---|---|---|
| Baseline | 3.2 | 4.3 |
| Week 1 | 2.3 | 2.2 |
| Week 4 | 2.2 | 3.3 |
| Week 8 | 2.3 | 3.3 |
| Week 12 | 2.2 | 2.2 |
| Week 16 | 1.1 | 1.1 |
| Week 20 | 1.2 | 2.2 |
| Week 24 | 2.4 | 1.2 |
| Week 28 | 3.5 | 2.3 |
| Week 32 | 2.5 | 1.3 |
| Week 36 | 1.4 | 1.2 |
| Week 40 | 2.7 | 2.4 |
| Week 44 | 1.5 | 1.3 |
| Week 48 | 0 | 1.2 |
| Week 52 | 1.4 | 0 |
| Week 56 | 3.0 | 0 |
| Week 60 | 1.6 | 1.6 |
| Week 64 | 1.8 | 0 |
| Week 68 | 1.9 | 0 |
| Week 72 | 0 | 0 |
CST was defined as the mean thickness from the inner limiting membrane to the retinal pigment epithelial over the 1 millimetre (mm) central subfield. CST was measured using spectral domain optical coherence tomography (SD-OCT). Negative change from baseline values denotes improvement. This analysis used a MMRM model.
| μm | Arm A: Vamikibart + Ranibizumab | Arm B: Ranibizumab |
|---|---|---|
| Change From Baseline in Central Subfield Thickness (CST) Averaged Over Week 44 and Week 48 in Treatment-naïve Participants | -202.4 ± 10.63 | -192.4 ± 10.11 |
CST was defined as the mean thickness from the inner limiting membrane to the retinal pigment epithelial over the 1 mm central subfield. CST was measured using SD-OCT. Negative change from baseline values denotes improvement. This analysis used a MMRM model.
| micrometre (μm) | Arm A: Vamikibart + Ranibizumab | Arm B: Ranibizumab |
|---|---|---|
| Change From Baseline in CST Averaged Over Week 44 and Week 48 in Previously Treated Participants | -194.4 ± 19.58 | -171.2 ± 18.79 |
CST was defined as the mean thickness from the inner limiting membrane to the retinal pigment epithelial over the 1 mm central subfield. CST was measured using SD-OCT. Negative change from baseline values denotes improvement. This analysis used an MMRM model.
| μm | Arm A: Vamikibart + Ranibizumab | Arm B: Ranibizumab |
|---|---|---|
| Change From Baseline in CST Averaged Over Week 44 and Week 48 in Overall ITT Population | -201.6 ± 8.33 | -178.8 ± 8.15 |
CST was defined as the mean thickness from the inner limiting membrane to the retinal pigment epithelial over the 1 mm central subfield. CST was measured using SD-OCT. Negative change from baseline values denotes improvement. This analysis used an MMRM model.
| μm | Arm A: Vamikibart + Ranibizumab | Arm B: Ranibizumab |
|---|---|---|
| Change From Baseline in CST Averaged Over Week 32 and Week 36 in Treatment-naïve Participants | -197.9 ± 10.26 | -180.3 ± 9.97 |
CST was defined as the mean thickness from the inner limiting membrane to the retinal pigment epithelial over the 1 mm central subfield. CST was measured using SD-OCT. Negative change from baseline values denotes improvement. This analysis used an MMRM model.
| μm | Arm A: Vamikibart + Ranibizumab | Arm B: Ranibizumab |
|---|---|---|
| Change From Baseline in CST Averaged Over Week 32 and Week 36 in Previously Treated Participants | -177.2 ± 18.38 | -150.0 ± 18.38 |
CST was defined as the mean thickness from the inner limiting membrane to the retinal pigment epithelial over the 1 mm central subfield. CST was measured using SD-OCT. Negative change from baseline values denotes improvement. This analysis used an MMRM model.
| μm | Arm A: Vamikibart + Ranibizumab | Arm B: Ranibizumab |
|---|---|---|
| Change From Baseline Averaged Over Week 32 and Week 36 in Overall ITT Population | -191.4 ± 8.51 | -172.1 ± 8.38 |
CST was defined as the mean thickness from the inner limiting membrane to the retinal pigment epithelial over the 1 mm central subfield. CST was measured using SD-OCT. Negative change from baseline values denotes improvement. This analysis used an MMRM model.
| μm | Arm A: Vamikibart + Ranibizumab | Arm B: Ranibizumab |
|---|---|---|
| Change From Baseline in CST Averaged Over Week 20 and Week 24 in Treatment-naïve Participants | -184.3 ± 10.05 | -169.7 ± 9.89 |
CST was defined as the mean thickness from the inner limiting membrane to the retinal pigment epithelial over the 1 mm central subfield. CST was measured using SD-OCT. Negative change from baseline values denotes improvement. This analysis used an MMRM model.
| μm | Arm A: Vamikibart + Ranibizumab | Arm B: Ranibizumab |
|---|---|---|
| Change From Baseline in CST Averaged Over Week 20 and Week 24 in Previously Treated Participants | -163.2 ± 17.75 | -120.2 ± 17.65 |
CST was defined as the mean thickness from the inner limiting membrane to the retinal pigment epithelial over the 1 mm central subfield. CST was measured using SD-OCT. Negative change from baseline values denotes improvement. This analysis used an MMRM model.
| μm | Arm A: Vamikibart + Ranibizumab | Arm B: Ranibizumab |
|---|---|---|
| Change From Baseline in CST Averaged Over Week 20 and Week 24 in Overall ITT Population | -176.1 ± 9.89 | -153.9 ± 9.80 |
CST was defined as the mean thickness from the inner limiting membrane to the retinal pigment epithelial over the 1 mm central subfield. CST was measured using SD-OCT. Negative change from baseline values denotes improvement. This analysis used an MMRM model.
| μm | Arm A: Vamikibart + Ranibizumab | Arm B: Ranibizumab |
|---|---|---|
| Baseline | 493.0 ± 11.55 | 498.4 ± 14.10 |
| Change at Week 4 | -121.0 ± 9.82 | -92.2 ± 9.77 |
| Change at Week 8 | -138.9 ± 9.67 | -108.2 ± 9.59 |
| Change at Week 12 | -147.9 ± 9.63 | -125.3 ± 9.54 |
| Change at Week 16 | -158.6 ± 10.28 | -138.3 ± 10.19 |
| Change at Week 20 | -172.8 ± 10.11 | -149.8 ± 10.00 |
| Change at Week 24 | -174.1 ± 10.12 | -152.9 ± 10.02 |
| Change at Week 28 | -181.1 ± 10.53 | -154.1 ± 10.38 |
| Change at Week 32 | -186.4 ± 8.87 | -165.6 ± 8.77 |
| Change at Week 36 | -191.1 ± 9.58 | -174.9 ± 9.33 |
| Change at Week 40 | -193.4 ± 8.92 | -166.7 ± 8.76 |
| Change at Week 44 | -197.3 ± 8.95 | -172.7 ± 8.73 |
| Change at Week 48 | -200.1 ± 9.04 | -179.2 ± 8.84 |
| Change at Week 52 | -172.7 ± 12.92 | -136.9 ± 12.25 |
| Change at Week 56 | -173.8 ± 11.43 | -129.2 ± 10.99 |
| Change at Week 60 | -155.5 ± 13.18 | -130.6 ± 12.65 |
| Change at Week 64 | -161.4 ± 13.65 | -163.0 ± 13.44 |
| Change at Week 68 | -160.1 ± 11.26 | -136.6 ± 10.96 |
| Change at Week 72 | -159.5 ± 11.62 | -154.3 ± 11.55 |
Absence of DME was defined as CST \< 325 μm for Spectralis SD-OCT, or \< 315 μm for Cirrus SD-OCT or Topcon SD-OCT. Percentages have been rounded off.
| percentage of participants | Arm A: Vamikibart + Ranibizumab | Arm B: Ranibizumab |
|---|---|---|
| Baseline | 0 (NA to NA) | 2.1 (0.0 to 5.0) |
| Week 4 | 31.1 (21.5 to 40.7) | 25.8 (16.7 to 34.9) |
| Week 8 | 45.3 (34.8 to 55.9) | 37.8 (27.8 to 47.8) |
| Week 12 | 47.1 (36.6 to 57.6) | 46.2 (35.9 to 56.4) |
| Week 16 | 57.5 (47.1 to 67.9) | 49.4 (38.9 to 59.9) |
| Week 20 | 64.2 (53.8 to 74.6) | 60.7 (50.5 to 70.8) |
| Week 24 | 65.9 (55.8 to 76.0) | 66.3 (56.3 to 76.3) |
| Week 28 | 75.6 (66.3 to 84.9) | 66.7 (56.8 to 76.6) |
| Week 32 | 75.3 (65.7 to 85.0) | 67.1 (56.7 to 77.5) |
| Week 36 | 75.3 (65.5 to 85.2) | 73.2 (63.6 to 82.8) |
| Week 40 | 77.3 (67.9 to 86.8) | 70.2 (60.5 to 80.0) |
| Week 44 | 80.6 (71.1 to 90.1) | 75.9 (66.5 to 85.4) |
| Week 48 | 79.4 (69.8 to 89.0) | 72.5 (62.7 to 82.3) |
| Week 52 | 70.6 (59.8 to 81.4) | 55.6 (44.7 to 66.4) |
| Week 56 | 67.6 (56.5 to 78.8) | 57.3 (46.1 to 68.5) |
| Week 60 | 62.3 (50.1 to 74.5) | 62.5 (50.6 to 74.4) |
| Week 64 | 59.6 (46.9 to 72.4) | 62.3 (49.2 to 75.3) |
| Week 68 | 58.5 (45.2 to 71.8) | 61.2 (47.6 to 74.9) |
| Week 72 | 61.5 (48.3 to 74.8) | 62.2 (48.1 to 76.4) |
The absence of IRF in the study eye (defined as IRF absent or definite outside center subfield only) was assessed by the central reading center using SD-OCT. The percentage of participants with absence of IRF at foveal center are reported. Percentages have been rounded off.
| percentage of participants | Arm A: Vamikibart + Ranibizumab | Arm B: Ranibizumab |
|---|---|---|
| Baseline | 19.6 | 22.3 |
| Week 4 | 53.9 | 47.8 |
| Week 12 | 60.5 | 51.1 |
| Week 24 | 69.5 | 69.8 |
| Week 36 | 70.4 | 71.1 |
| Week 48 | 78.8 | 78.2 |
| Week 72 | 71.2 | 75.6 |
The absence of SRF in the study eye (defined as SRF absent or definite outside center subfield only) was assessed by the central reading center using SD-OCT. The percentage of participants with absence of SRF at the foveal center are reported. Percentages have been rounded off.
| percentage of participants | Arm A: Vamikibart + Ranibizumab | Arm B: Ranibizumab |
|---|---|---|
| Baseline | 60.4 | 63.8 |
| Week 4 | 89.9 | 82.2 |
| Week 12 | 98.9 | 93.4 |
| Week 24 | 98.8 | 96.5 |
| Week 36 | 100 | 96.4 |
| Week 48 | 98.5 | 97.4 |
| Week 72 | 98.1 | 100 |
Collected over Up to Week 72. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Arm A: Vamikibart + Ranibizumab | 1/93 (1.1%) | 22/93 (23.7%) | 38/93 (40.9%) |
| Arm B: Ranibizumab | 2/94 (2.1%) | 17/94 (18.1%) | 48/94 (51.1%) |
| Event | Arm A: Vamikibart + Ranibizumab | Arm B: Ranibizumab |
|---|---|---|
| Cerebrovascular accidentNervous system disorders | 3/93 | 0/94 |
| Myocardial infarctionCardiac disorders | 2/93 | 0/94 |
| Retinal occlusive vasculitisEye disorders | 2/93 | 0/94 |
| VitritisEye disorders | 2/93 | 0/94 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 2/93 | 0/94 |
| HypoglycaemiaMetabolism and nutrition disorders | 0/93 | 2/94 |
| Carotid artery stenosisNervous system disorders | 0/93 | 2/94 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 0/93 | 2/94 |
| HypotensionVascular disorders | 1/93 | 2/94 |
| Peripheral arterial occlusive diseaseVascular disorders | 1/93 | 2/94 |
| Event | Arm A: Vamikibart + Ranibizumab | Arm B: Ranibizumab |
|---|---|---|
| Diabetic retinal oedemaEye disorders | 9/93 | 16/94 |
| COVID-19Infections and infestations | 9/93 | 2/94 |
| HypertensionVascular disorders | 7/93 | 9/94 |
| Conjunctival haemorrhageEye disorders | 8/93 | 8/94 |
| Urinary tract infectionInfections and infestations | 3/93 | 8/94 |
| NasopharyngitisInfections and infestations | 2/93 | 7/94 |
| Diabetes mellitusMetabolism and nutrition disorders | 4/93 | 6/94 |
| CataractEye disorders | 5/93 | 3/94 |
| FallInjury, poisoning and procedural complications | 1/93 | 5/94 |
ITT population included all randomized participants grouped according to the treatment assigned at randomization.
| Age, Continuous(years) | Arm A: Vamikibart + Ranibizumab | Arm B: Ranibizumab | Total |
|---|---|---|---|
| Mean | 61.7 ± 10.1 | 62.1 ± 9.3 | 61.9 ± 9.7 |
| Sex: Female, Male(Participants) | Arm A: Vamikibart + Ranibizumab | Arm B: Ranibizumab | Total |
|---|---|---|---|
| Female | 31 | 39 | 70 |
| Male | 62 | 55 | 117 |
| Ethnicity (NIH/OMB)(Participants) | Arm A: Vamikibart + Ranibizumab | Arm B: Ranibizumab | Total |
|---|---|---|---|
| Hispanic or Latino | 6 | 14 | 20 |
| Not Hispanic or Latino | 56 | 56 | 112 |
| Unknown or Not Reported | 31 | 24 | 55 |
| Race (NIH/OMB)(Participants) | Arm A: Vamikibart + Ranibizumab | Arm B: Ranibizumab | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 7 | 3 | 10 |
| White | 45 | 60 | 105 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 41 | 31 | 72 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing
Ran from Dec 2021 to primary completion in Apr 2024, 28 months.
Results were first posted in Oct 2025, 1 year 5 months after primary completion. A results delay was requested in Apr 2025.
Of 32 industry-sponsored phase 2 interventional studies under Macular Edema, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 28. This study's 28 months is above that.
Counting every sponsor, half of 50 studies reached it within 19 months; a quarter within 15 and three quarters within 32.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Vamikibart